233 related articles for article (PubMed ID: 24691269)
1. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure.
Úri K; Fagyas M; Mányiné Siket I; Kertész A; Csanádi Z; Sándorfi G; Clemens M; Fedor R; Papp Z; Édes I; Tóth A; Lizanecz E
PLoS One; 2014; 9(4):e87845. PubMed ID: 24691269
[TBL] [Abstract][Full Text] [Related]
2. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system.
Epelman S; Tang WH; Chen SY; Van Lente F; Francis GS; Sen S
J Am Coll Cardiol; 2008 Aug; 52(9):750-4. PubMed ID: 18718423
[TBL] [Abstract][Full Text] [Related]
3. Increasing serum soluble angiotensin-converting enzyme 2 activity after intensive medical therapy is associated with better prognosis in acute decompensated heart failure.
Shao Z; Shrestha K; Borowski AG; Kennedy DJ; Epelman S; Thomas JD; Tang WH
J Card Fail; 2013 Sep; 19(9):605-10. PubMed ID: 24054336
[TBL] [Abstract][Full Text] [Related]
4. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes.
Epelman S; Shrestha K; Troughton RW; Francis GS; Sen S; Klein AL; Tang WH
J Card Fail; 2009 Sep; 15(7):565-71. PubMed ID: 19700132
[TBL] [Abstract][Full Text] [Related]
5. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study.
Ortiz-Pérez JT; Riera M; Bosch X; De Caralt TM; Perea RJ; Pascual J; Soler MJ
PLoS One; 2013; 8(4):e61695. PubMed ID: 23630610
[TBL] [Abstract][Full Text] [Related]
6. Circulating ACE2 activity correlates with cardiovascular disease development.
Úri K; Fagyas M; Kertész A; Borbély A; Jenei C; Bene O; Csanádi Z; Paulus WJ; Édes I; Papp Z; Tóth A; Lizanecz E
J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27965422
[TBL] [Abstract][Full Text] [Related]
7. Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Almengló C; Couselo-Seijas M; Agra RM; Varela-Román A; García-Acuña JM; González-Peteiro M; González-Juanatey JR; Eiras S; Álvarez E
J Mol Med (Berl); 2021 Dec; 99(12):1741-1753. PubMed ID: 34529122
[TBL] [Abstract][Full Text] [Related]
8. Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients.
Li S; Wang Z; Yang X; Hu B; Huang Y; Fan S
Peptides; 2017 Apr; 90():63-68. PubMed ID: 28223093
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation.
Wallentin L; Lindbäck J; Eriksson N; Hijazi Z; Eikelboom JW; Ezekowitz MD; Granger CB; Lopes RD; Yusuf S; Oldgren J; Siegbahn A
Eur Heart J; 2020 Nov; 41(41):4037-4046. PubMed ID: 32984892
[TBL] [Abstract][Full Text] [Related]
10. [Role of ACE2-Ang (1-7)-Mas receptor axis in heart failure with preserved ejection fraction with hypertension].
Yu J; Wu Y; Zhang Y; Zhang L; Ma Q; Luo X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):738-746. PubMed ID: 30124209
[TBL] [Abstract][Full Text] [Related]
11. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
Sama IE; Ravera A; Santema BT; van Goor H; Ter Maaten JM; Cleland JGF; Rienstra M; Friedrich AW; Samani NJ; Ng LL; Dickstein K; Lang CC; Filippatos G; Anker SD; Ponikowski P; Metra M; van Veldhuisen DJ; Voors AA
Eur Heart J; 2020 May; 41(19):1810-1817. PubMed ID: 32388565
[TBL] [Abstract][Full Text] [Related]
12. Soluble angiotensin converting enzyme 2 levels in chronic heart failure is associated with decreased exercise capacity and increased oxidative stress-mediated endothelial dysfunction.
Shao Z; Schuster A; Borowski AG; Thakur A; Li L; Wilson Tang WH
Transl Res; 2019 Oct; 212():80-88. PubMed ID: 31323221
[TBL] [Abstract][Full Text] [Related]
13. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology.
Pinto YM; de Smet BG; van Gilst WH; Scholtens E; Monnink S; de Graeff PA; Wesseling H
Cardiovasc Res; 1993 Nov; 27(11):1933-8. PubMed ID: 8287399
[TBL] [Abstract][Full Text] [Related]
14. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID-19 and correlates with specific inflammatory and endothelial markers.
Lundström A; Ziegler L; Havervall S; Rudberg AS; von Meijenfeldt F; Lisman T; Mackman N; Sandén P; Thålin C
J Med Virol; 2021 Oct; 93(10):5908-5916. PubMed ID: 34138483
[TBL] [Abstract][Full Text] [Related]
15. The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction.
Hisatake S; Kiuchi S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32458985
[TBL] [Abstract][Full Text] [Related]
16. Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study).
Hussain A; Tang O; Sun C; Jia X; Selvin E; Nambi V; Folsom A; Heiss G; Zannad F; Mosley T; Virani SS; Coresh J; Boerwinkle E; Yu B; Cunningham JW; Shah AM; Solomon SD; de Lemos JA; Hoogeveen RC; Ballantyne CM
Am J Cardiol; 2021 May; 146():15-21. PubMed ID: 33539861
[TBL] [Abstract][Full Text] [Related]
17. The interplay between renin-angiotensin system activation, abnormal myocardial deformation and neurohumoral activation in hypertensive heart disease: a speckle tracking echocardiography study.
Ikonomidis I; Tzortzis S; Tsantes A; Ntai K; Triantafyllidi H; Trivilou P; Katsimaglis G; Dima K; Parissis J; Lekakis J
Int J Cardiovasc Imaging; 2017 Mar; 33(3):323-329. PubMed ID: 27787699
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both.
Yan RT; White M; Yan AT; Yusuf S; Rouleau JL; Maggioni AP; Hall C; Latini R; Afzal R; Floras J; Masson S; McKelvie RS;
Am J Cardiol; 2005 Sep; 96(5):698-704. PubMed ID: 16125499
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Proteomic Correlates of Plasma ACE2 (Angiotensin-Converting Enzyme 2) in Human Heart Failure.
Chirinos JA; Cohen JB; Zhao L; Hanff T; Sweitzer N; Fang J; Corrales-Medina V; Anmar R; Morley M; Zamani P; Bhattacharya P; Brandimarto J; Jia Y; Basso MD; Wang Z; Ebert C; Ramirez-Valle F; Schafer PH; Seiffert D; Gordon DA; Cappola T
Hypertension; 2020 Nov; 76(5):1526-1536. PubMed ID: 32981365
[TBL] [Abstract][Full Text] [Related]
20. N-terminal-probrain natriuretic peptide and echocardiography in patients with systolic heart failure.
Al-Meslmani BM; Fahoum SK; Shamia MG
Saudi Med J; 2005 Nov; 26(11):1695-8. PubMed ID: 16311650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
